Acridine–O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity

Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma

(2021) Malobika Chakravarty et al.   Frontiers in Oncology

Novel Therapies for Glioblastoma

(2020) Elisa K. Liu et al.   Current Neurology and Neuroscience Reports

Cytotoxicity Burst? Differentiating Specific from Nonspecific Effects in Tox21 in Vitro Reporter Gene Assays

(2020) Beate I. Escher et al.   ENVIRONMENTAL HEALTH PERSPECTIVES

Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors

(2020) Evgenii Belykh et al.   Frontiers in Oncology

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

(2019) Carl C. Ward et al.   ACS Chemical Biology

Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors

(2019) Christopher B Jackson et al.   CANCER RESEARCH

C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage

(2019) Zhikuan Yang et al.   Frontiers in Oncology

Repurposing quinacrine for treatment-refractory cancer

(2019) Derek B. Oien et al.   SEMINARS IN CANCER BIOLOGY

Statistical determination of synergy based on Bliss definition of drugs independence

(2019) Eugene Demidenko et al.   PLoS One

Synthesis, spectroscopic studies and biological evaluation of acridine derivatives: The role of aggregation on the photodynamic efficiency

(2018) Carles Felip-León et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Ten-year survival in glioblastoma. A systematic review

(2018) Tomasz Tykocki et al.   JOURNAL OF CLINICAL NEUROSCIENCE

β-Ecdysterone protects SH-SY5Y cells against β-amyloid-induced apoptosis via c-Jun N-terminal kinase- and Akt-associated complementary pathways

(2018) Tianjiao Xu et al.   LABORATORY INVESTIGATION

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

(2018) Shabierjiang JIAPAER et al.   NEUROLOGIA MEDICO-CHIRURGICA

Medicinal chemistry of acridine and its analogues

(2018) Parteek Prasher et al.   MedChemComm

Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide

(2018) Tor‐Christian Johannessen et al.   INTERNATIONAL JOURNAL OF CANCER

Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU

(2017) Yameng Wang et al.   ACS Medicinal Chemistry Letters

An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines

(2017) Kyle R. Roell et al.   Frontiers in Pharmacology

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

(2017) Antoine Daina et al.   Scientific Reports

Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: Designed to release a DNA cross-linking agent and an inhibitor of O6-alkylguanine-DNA alkyltransferase

(2016) Guohui Sun et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Hybrid molecules: The privileged scaffolds for various pharmaceuticals

(2016) Shaveta et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking

(2016) Guohui Sun et al.   MOLECULES

Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response

(2016) Andrew A. Beharry et al.   PLoS One

Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors

(2015) Karl-Heinz Tomaszowski et al.   MOLECULAR PHARMACEUTICS

DNA binders in clinical trials and chemotherapy

(2014) Asfa Ali et al.   BIOORGANIC & MEDICINAL CHEMISTRY

AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research

(2014) Haibin Liu et al.   Journal of Chemical Information and Modeling

Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF- B, and Cell-Cycle Progression in Non-Small Cell Lung Cancer

(2014) J. K. T. Dermawan et al.   MOLECULAR CANCER THERAPEUTICS

Developing Bivalent Ligands to Target CUG Triplet Repeats, the Causative Agent of Myotonic Dystrophy Type 1

(2013) Amin Haghighat Jahromi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases

(2012) Qi Qi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

(2011) Reza Ehsanian et al.   Cell Communication and Signaling

Curaxins: A New Family of Non-genotoxic Multitargeted Anticancer Agents

(2011) Valeria Di Bussolo et al.   ChemMedChem

6-Carboxyfluorescein and structurally similar molecules inhibit DNA binding and repair by O6-alkylguanine DNA alkyltransferase

(2011) Manana Melikishvili et al.   DNA REPAIR

Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity

(2011) Ranjan Preet et al.   INTERNATIONAL JOURNAL OF CANCER

Selective inhibition of MBNL1–CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2) †

(2011) Chun-Ho Wong et al.   NUCLEIC ACIDS RESEARCH

Standards for photoluminescence quantum yield measurements in solution (IUPAC Technical Report)

(2011) Albert M. Brouwer   PURE AND APPLIED CHEMISTRY

Curaxins: Anticancer Compounds That Simultaneously Suppress NF- B and Activate p53 by Targeting FACT

(2011) A. V. Gasparian et al.   Science Translational Medicine

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide

(2010) Yuichi Sato et al.   CANCER BIOLOGY & THERAPY

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin

(2010) Tanvi S. Jani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

(2009) Katerina Gurova   Future Oncology

9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways

(2009) C Guo et al.   ONCOGENE

Substitution of Aminomethyl at the Meta-Position Enhances the Inactivation ofO6-Alkylguanine-DNA Alkyltransferase byO6-Benzylguanine

(2008) Gary T. Pauly et al.   JOURNAL OF MEDICINAL CHEMISTRY